Cargando…

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial

The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Manda, Naoki, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587523/
https://www.ncbi.nlm.nih.gov/pubmed/30311367
http://dx.doi.org/10.1111/dom.13557
_version_ 1783429085017407488
author Cho, Kyu Yong
Nakamura, Akinobu
Omori, Kazuno
Takase, Takahiro
Miya, Aika
Manda, Naoki
Kurihara, Yoshio
Aoki, Shin
Atsumi, Tatsuya
Miyoshi, Hideaki
author_facet Cho, Kyu Yong
Nakamura, Akinobu
Omori, Kazuno
Takase, Takahiro
Miya, Aika
Manda, Naoki
Kurihara, Yoshio
Aoki, Shin
Atsumi, Tatsuya
Miyoshi, Hideaki
author_sort Cho, Kyu Yong
collection PubMed
description The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non‐inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT‐proBNP, P < 0.01; ACR, P = 0.02), and the change in NT‐proBNP correlated negatively with baseline NT‐proBNP level (ρ = −0.68, P < 0.01) and log‐converted ACR (ρ = −0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events.
format Online
Article
Text
id pubmed-6587523
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-65875232019-07-02 Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial Cho, Kyu Yong Nakamura, Akinobu Omori, Kazuno Takase, Takahiro Miya, Aika Manda, Naoki Kurihara, Yoshio Aoki, Shin Atsumi, Tatsuya Miyoshi, Hideaki Diabetes Obes Metab Brief Reports The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non‐inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT‐proBNP, P < 0.01; ACR, P = 0.02), and the change in NT‐proBNP correlated negatively with baseline NT‐proBNP level (ρ = −0.68, P < 0.01) and log‐converted ACR (ρ = −0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events. Blackwell Publishing Ltd 2018-11-08 2019-03 /pmc/articles/PMC6587523/ /pubmed/30311367 http://dx.doi.org/10.1111/dom.13557 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Reports
Cho, Kyu Yong
Nakamura, Akinobu
Omori, Kazuno
Takase, Takahiro
Miya, Aika
Manda, Naoki
Kurihara, Yoshio
Aoki, Shin
Atsumi, Tatsuya
Miyoshi, Hideaki
Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title_full Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title_fullStr Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title_full_unstemmed Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title_short Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
title_sort effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: an open‐label, prospective, randomized, parallel‐group comparison trial
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587523/
https://www.ncbi.nlm.nih.gov/pubmed/30311367
http://dx.doi.org/10.1111/dom.13557
work_keys_str_mv AT chokyuyong effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT nakamuraakinobu effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT omorikazuno effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT takasetakahiro effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT miyaaika effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT mandanaoki effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT kuriharayoshio effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT aokishin effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT atsumitatsuya effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial
AT miyoshihideaki effectofswitchingfrompioglitazonetothesodiumglucosecotransporter2inhibitordapagliflozinonbodyweightandmetabolismrelatedfactorsinpatientswithtype2diabetesmellitusanopenlabelprospectiverandomizedparallelgroupcomparisontrial